May 23, 2005
For Immediate Release
Gastroesophageal Reflux Disease (GERD) Treatment Moving to Endoscopic Repair, According to May 2005 Issue of MedMarkets from MedMarket Diligence, LLC
FOOTHILL RANCH, CA — Limitations in drug treatment due to their long term cost for management of gastroesophageal reflux disease (GERD) or in the cost and invasiveness of open surgical treatment via Nissen fundoplication are driving the market development of endoscopic technologies for treatment of GERD. These developments are reviewed in the May 2005 issue of MedMarkets.
"With drug costs at over $2,000 per year, and with the alternative of an invasive $15,000 inpatient surgical procedure, it should be no surprise that endoscopic technologies are gaining a sure foothold in clinical practice and will generate good device revenues for manufacturers," says Patrick Driscoll, publisher of MedMarkets. According to Driscoll, while endoscopic repair of GERD is currently performed under 10,000 times annually now, this will triple over the next few years as surgeons adopt techniques employing a range of devices from Barrx, Boston Scientific, CR Bard, Curon Medical, Medtronic, NDO Surgical, Wilson Cook and others. These devices employ various ablation technologies, bulking agents, suturing devices and plication devices in endoscopic procedures to restore the function of the gastroesophageal sphincter.
The May 2005 issue of MedMarkets reviews the clinical background, patient caseload, costs, and alternative treatments -- including drugs and devices -- for the management of GERD.
MedMarkets is published 12 times annually by MedMarket Diligence. Coverage encompasses medical device, biotech, biomaterials and the range of technologies encompassing device market developments and analysis of Interventional Cardiology, Cardiovascular Surgery, Orthopedics/Musculoskeletal, Abdominal & Thoracic Surgery, Gynecology, Oncology, Neurology & Neurosurgery and other clinical sectors. Past coverage may be reviewed at www.mediligence.com/archive2005.html.
MedMarket Diligence provides tactical decision-making solutions on medical
technology to the medical products and investment industries. The company
MedMarkets newsletter, a monthly analysis of the market implications of new
medical technologies, and dedicated reports on technology markets. For
additional details, contact Patrick Driscoll at
email or call
949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.